Showing 13–24 of 37 results
Throughout early discovery and particularly for market release, biologic drug candidates require mechanism-of-action (MOA)-based functional, cellular assays as characterisation tools…
Watch NowMonoclonal antibodies (MAbs) represent one of the fastest growing classes of biotherapeutic molecules today. While many technologies exist for generating…
Read MoreDiscoveRx has developed a panel of over 120 characterized GPCR cell lines that monitor receptor activity using interaction with human…
Read MoreCystic fibrosis (CF) patients have mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel that result in reduced…
Read MoreDiscoveRx has pioneered a novel enzyme complementation system to monitor cellular events such as protein translocation, protein interactions, and degradation…
Read MoreFollowing the recent regulatory approvals of a number of checkpoint inhibitor therapeutics, development of a wide array of immunomodulatory therapeutic…
Read MoreInterest in GPCR ligand bias has increased in recent years due to evidence that positive and negative aspects of drug…
Read MoreThe clinical success of an ever-increasing array of biologics has led to the development of a wide spectrum of immunomodulatory…
Read MoreOrphan GPCRs continue to represent a target class with immense potential for the discovery of novel therapeutic compounds. In spite…
Read MoreReporter genes are a well-established method used to develop cell-based assays for testing drugs that inhibit targets involved in specific…
Read MoreDiscoveRx® has pioneered a novel enzyme complementation system to monitor cellular events such as protein translocation, protein interactions, and degradation…
Read MoreThe PathHunter™ technology from DiscoveRx is an adaptation of Enzyme Fragment Complementation (EFC) that provides a novel, generic cell-based assay…
Read More
